CooperDA, Acute AIDS retrovirus infection: Definition of a clinical illness associated with seroconversion, Lancet1985, i: 537–40.
2.
HoDD, Primary human T-lymphotropic virus type III infection, Annals of Internal Medicine1985, 103: 880–83.
3.
LangeJMA, Distinct IgG recognition patterns during progression of subclinical and clinical infection with LAV/HTLV-III, British Medical Journal1985, 292: 228–30; GoudsmitJ, Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection, Lancet1986, ii: 177–80.
4.
CurranJW, The epidemiology of AIDS: Current status and future prospects, Science1985, 229: 1352–57.
5.
JaffeH, Natural history of HTLV-III/LAV infection in a cohort of gay men, in Program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 28-October 1, 1986.
6.
RedfieldRR, The natural history of HTLV-III/LAV infection, in Program and abstracts of the Second International Conference on AIDS, Paris, June 23–25, 1986.
7.
Mathur-WaghU, Longitudinal study of persistent generalized lymphadenopathy in homosexual men: Relation to the acquired immunodeficiency syndrome, Lancet1984, i: 1033–38.
8.
AbramsDIMessTPVolberdingP, Lymphadenopathy: Update of a 40-month prospective study; Paper presented at the International Conference on AIDS, Atlanta, Ga., April 15, 1985.
9.
GoedertJJ, Three year incidence of AIDS among HTLV-III infected risk group members: A comparison of five cohorts, Science1986, 231: 992–95.
10.
Curran, supra note 4; JaffeHW, The acquired immunodeficiency syndrome in a cohort of homosexual men: A six-year follow-up study, Annals of Internal Medicine1985, 103: 210–14; MetrokaCE, Generalized lymphadenopathy in homosexual men, Annals of Internal Medicine1983, 99: 585–91.
11.
KleinRS, Oral candidiasis in high risk patients as the initial manifestation of the acquired immunodeficiency syndrome, New England Journal of Medicine1984, 311: 354–58.
12.
GottliebMSFaheyJL, The clinical laboratory in the diagnosis and management of AIDS and HTLV-III/LAV infections, Plenary Session II of the Program and abstracts of the Second International Conference on AIDS, Paris, June 23–25, 1986.
13.
KovacsJA, Pneumocystis carinii pneumonia: A comparison between patients with acquired immunodeficiency syndrome and patients with other immunodeficiencies, Annals of Internal Medicine1984, 100: 663–71.
14.
GordinFM, Adverse reactions to trimethoprim-sulfamethoxazole in patients with AIDS, Annals of Internal Medicine1984, 100: 495–99.
15.
HaverkosHW, Assessment of therapy for Pneumocystis carinii pneumonia, American Journal of Medicine1984, 76: 501–8.
16.
HughesWTSmithBC, Efficiency of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonia, Antimicrobial Agents and Chemotherapy1984, 26: 436.
17.
Klein, supra note 11.
18.
CurranJW, The epidemiology of AIDS: Current status and future prospects, Science1985, 229: 1351–57.
19.
ZugerA, Cryptococcal disease in patients with acquired immunodeficiency syndrome, Annals of Internal Medicine1986, 104: 134–40.
20.
BennettJE, A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis, New England Journal of Medicine1979, 301: 126–31.
21.
LuftBJ, Toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome, Journal of the American Medical Association1984, 252: 913–17.
22.
WongB, Central nervous system toxoplasmosis in homosexual men and parenteral drug abusers, Annals of Internal Medicine1984, 100: 36–42.
23.
SoaveR, Cryptosporidiosis in homosexual men, Annals of Internal Medicine1984, 100: 504–11.
24.
HawkinsCC, Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome, Annals of Internal Medicine1986, 105: 184–88.
25.
ZakowskiP, Disseminated Mycobacterium avium-intracellulare infection in homosexual men dying of acquired immunodeficiency syndrome, Journal of the American Medical Association1982, 248: 1980–82.
26.
PitchenikAE, Tuberculosis, atypical mycobacteriosis and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida, Annals of Internal Medicine1984, 101: 641–45.
27.
MintzL, Cytomegalovirus infections in homosexual men: An epidemiological study, Annals of Internal Medicine1983, 99: 326–29; LangeM, Cytomegalovirus isolation from healthy homosexual men, Journal of the American Medical Association1984, 252: 1908–10.
28.
LaurenceJ, AIDS report, CMV infections in AIDS patients, Infections in Surgery1986, 603–10; TapperML, Adrenal necrosis in the acquired immunodeficiency syndrome, Annals of Internal Medicine1984, 100: 239–41.
29.
MasurH, Effect of 9-(1,3-dihydroxy-2-propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men, Annals of Internal Medicine1986, 104: 41–44; KoretzSH, Treatment of serious cytomegalovirus infection with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies, New England Journal of Medicine1986, 314: 801–5.
30.
MitsuyasuRTGroopmanJE, Biology and therapy for Kaposi's sarcoma, Seminars in Oncology1984, 11: 53–59.
31.
MintzerDM, Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome, Annals of Internal Medicine1985, 102: 200–202.
32.
MarmorM, Risk factors for Kaposi's sarcoma in homosexual men, Lancet1982, i: 1083–87.
33.
DrewWL, Declining prevalence of Kaposi's sarcoma in homosexual AIDS patients is paralleled by declining incidence of CMV infection, in Program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., September 28–October 1, 1986.
34.
ZieglerJL, Non-Hodgkin's lymphoma in 90 homosexual men, New England Journal of Medicine1984, 311: 565–70.
35.
IoachimHCCooperMCHellmanGC, Lymphomas in men at high risk for acquired immunodeficiency syndrome (AIDS): A study of 21 cases, Cancer1985, 56: 2831–42.
36.
SchoeppelSC, Hodgkin's disease in homosexual men with generalized lymphadenopathy, Annals of Internal Medicine1985, 102: 68–70.
37.
SniderWD, Neurologic complications of acquired immunodeficiency syndrome: Analysis of 50 patients, Annals of Neurology1983, 14: 403–18.
38.
NaviaBA, The AIDS dementia complex II: Neuropathology, Annals of Neurology1986, 19: 525–35; EpsteinLG, Progressive encephalopathy in children with acquired immunodeficiency syndrome, Annals of Neurology1985, 17: 488–96.
39.
ParksWPScottGB, An overview of pediatric AIDS: Approaches to diagnosis and outcome assessment, Background paper, Washington, D.C.: Committee on a National Strategy for AIDS, 1986.
40.
MarionRW, Human T-cell lymphotropic virus type III (HTLV-III/LAV) embryopathy: A new dysmorphic syndrome associated with intrauterine HTLV-III infection, American Journal of Diseases in Children1986, 140: 638–40.
41.
DarrowWW, Cofactors in the development of AIDS and AIDS-related conditions, in Program and abstracts of the Second International Conference on AIDS, Paris, France, June 23–25, 1986.
42.
CoutinhoRA, The natural history of LAV/HTLV-III infection, in Program and abstracts of the Second International Conference on AIDS, Paris, France, June 23–25, 1986.
43.
KatzJ, ed., The silent world of doctor and patient, New York: Free Press, 1984.
44.
GottliebMSFaheyJL, The clinical laboratory in the diagnosis and management of AIDS and HTLV-III/LAV infections, in Program and abstracts of the Second International Conference on AIDS, Paris, France, June 23–25, 1986.
45.
GoudsmitJ, Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection, Lancet1986, ii: 177–80.
46.
Lange, supra note 3.
47.
DalgleishAG, The CD4 (T4) antigen is an essential component antigen of the receptor for the AIDS retrovirus, Nature1984, 312: 763–67.
48.
HirschMSKaplanJC, Prospects of therapy for infections with human T-lymphotropic virus type III, Annals of Internal Medicine1985, 103: 750–55.
49.
LevineAM, Suramin antiviral therapy in the acquired immunodeficiency syndrome: Clinical, immunologic, and virologic results, Annals of Internal Medicine1985, 105: 32–37.
50.
RozenbaumW, Antimoniotungstate (HPA23) treatment of three patients with AIDS and one with prodrome, Lancet1985, i: 450–51.
51.
MitsuyaHBroderS, Inhibition of the in-vitro infectivity and cytopathic effect of HTLV-III/LAV by 2', 3'-dideoxynucleosides, Proceedings of the National Academy of Sciences USA1986, 83: 1911–15; YarchoanR, Administration of 3'azido-3'-deoxythymidine, an inhibitor of HTLV-III replication, to patients with AIDS or AIDS-related complex, Lancet1986, i: 575–80.
52.
Mitsuya, supra note 51.
53.
McCormickJB, Ribavirin suppresses replication of lymphadenopathy-associated virus in culture of human lymphocytes, Lancet1984, ii: 1367–69; RobertsRB, Effects of short term oral ribavirin in high risk patients for AIDS, in Program and abstracts of the Second International Conference on AIDS, Paris, June 23–25, 1986.
54.
SandstromEG, Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate, Lancet1985, i: 1480–82.
GriecoHM, In-vivo immunomodulation by isoprinosine in patients with the acquired immunodeficiency syndrome and related complexes, Annals of Internal Medicine1984, 101: 206–7; TsangPH, Modulation of T- and B-lymphocyte functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS), Journal of Clinical Microbiology1984, 4: 469–78.
57.
LaneHCFauciAS, Immunologic reconstitution in the acquired immunodeficiency syndrome, Annals of Internal Medicine1985, 103: 714–18.
58.
BertramJH, Protein A therapy with the Prosorba column in homosexual patients with idiopathic thrombocytopenic purpura-preliminary observations, in Program and abstracts of the Second International Conference on AIDS, Paris, June 23–25, 1986.
59.
Mitsuyasu, supra note 30.
60.
ArmstrongD, Treatment of infections in patients with the acquired immunodeficiency syndrome, Annals of Internal Medicine1985, 103: 738–43.
61.
MayerKH, HTLV-III screening and the blood supply: Public health policies and concerns, in WittMD, ed., AIDS: Legal, social and ethical considerations, Owings Mills, Md.: National Health Publishing, 1986, 35–39.
62.
MayerKH, Testing for HTLV-III and AIDS risk reduction: Clinical and epidemiological quandaries, in OstrowD, ed., The bio-behavioral control of AIDS, New York: Irvington Press, in press.
63.
FoxROdakaNPolkBF, Effect of learning HTLV-III/LAV antibody status on subsequent sexual activity, in Program and abstracts of the Second International Conference on AIDS, Paris, France, June 23–25, 1986.
64.
Nation's hospitals awakening to increasing AIDS caseload, in ThorntonTG, ed., AIDS Alert1986, 1: 117–20.